Sep 12th 2013 - Edison Investment Research today published a report on TiGenix entitled "Extending Knee Sales, Aiming For A Crohn’s Deal". In summary, the report says:
Tigenix is making solid progress in growing ChondroCelect sales for knee cartilage repair, with 2014 sales potentially in the €7.5-9m range. The July €6.5m funding provided cash into Q114, but management indicates a further €12m might be needed up to Q314. A deal on the Phase III Cx601 (cell therapy for fistulising Crohn’s disease) is anticipated with an upfront fee; non-dilutive funding is being actively explored. Phase IIa Cx611 data in April showed good responses in highly-refractory rheumatoid arthritis patients. The next Cx611 stage is in discussion but this is a massive opportunity.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »